Anika Therapeutics | ANIK - Ebit

Aktienkurs
14.76
Täglich Wechseln
-0.46 -3.02%
Monatlich
2.79%
Jährlich
8.21%
Q2 Prognose
14.36




Ebit Veränderung Datum
Abbott USD 2.54B 358M 2025-12
Agenus USD 14.4M 19.26M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 17.01M 2025-12
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Integra LifeSciences USD 66M 54.24M 2025-12
Intrexon USD -26.3M 2.91M 2024-06
J&J USD 5.11B 2.3B 2025-12
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
Ligand Pharmaceuticals USD 158.89M 115.32M 2025-09
MacroGenics USD -12.1M 32.26M 2025-12
Merit Medical Systems USD 54.2M 11.58M 2025-12
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
Sanofi EUR 1.7B 2.17B 2025-12
Smith & Nephew USD 440M 50M 2025-12
Stryker USD 1.97B 609M 2025-12
Surmodics USD 58K 380K 2025-06
Veracyte USD 24.63M 1.52M 2025-12
Xencor USD -53.63M 6.11M 2025-12
Zimmer Biomet Holdings USD 302.9M 35.4M 2025-12